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Abstract
Primary open angle glaucoma (POAG) is a complex disease with a major genetic contribution. Its prevalence varies greatly 
among ethnic groups, and is up to five times more frequent in black African populations compared to Europeans. So far, 
worldwide efforts to elucidate the genetic complexity of POAG in African populations has been limited. We conducted a 
genome-wide association study in 1113 POAG cases and 1826 controls from Tanzanian, South African and African American 
study samples. Apart from confirming evidence of association at TXNRD2 (rs16984299;  OR[T] 1.20; P = 0.003), we found 
that a genetic risk score combining the effects of the 15 previously reported POAG loci was significantly associated with 
POAG in our samples (OR 1.56; 95% CI 1.26–1.93; P = 4.79 × 10−5). By genome-wide association testing we identified a 
novel candidate locus, rs141186647, harboring EXOC4  (OR[A] 0.48; P = 3.75 × 10−8), a gene transcribing a component of 
the exocyst complex involved in vesicle transport. The low frequency and high degree of genetic heterogeneity at this region 
hampered validation of this finding in predominantly West-African replication sets. Our results suggest that established 
genetic risk factors play a role in African POAG, however, they do not explain the higher disease load. The high heteroge-
neity within Africans remains a challenge to identify the genetic commonalities for POAG in this ethnicity, and demands 
studies of extremely large size.
Introduction
Glaucoma is the leading cause of irreversible blindness world-
wide (Tham et al. 2014). The disease is an optic neuropathy 
characterized by loss of retinal ganglion cells resulting in 
peripheral visual field defects. Later in the disease process, the 
visual field defects may involve central vision leading to blind-
ness. Primary open-angle glaucoma (POAG) is the commonest 
subtype of glaucoma. Intraocular pressure (IOP), family his-
tory, age, and ancestry are established risk factors. In particu-
lar persons of African ancestry have 3–5 × increased risk of 
POAG, and have a more severe course of disease with a higher 
risk of blindness (Cook 2009; Kyari et al. 2013). This ethnic 
predilection along with the familial nature strongly suggests 
that genetic factors contribute to the pathogenesis of POAG.
Recently, progress has been made in the identification 
of associated variants using linkage analysis and genome-
wide association studies (GWAS). Rare variants with large 
effects have been identified in MYOC and OPTN, common 
variants with smaller effect have been reported in genomic 
regions that include CAV1-CAV2, CDC7-TGFRB3, TMCO1, 
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CDKN2B-AS1, ABCA1, AFAP1, GMDS, TXNRD2, ATXN2, 
FOXC1, GAS7, ARHGEF12, SIX6, 8q22 and PMM2 (Bailey 
et al. 2016; Burdon et al. 2011; Chen et al. 2014; Liu et al. 
2013; Hysi et al. 2014; Li et al. 2015; Springelkamp et al. 
2015; Thorleifsson et al. 2010; Wiggs et al. 2012). However, 
these loci explain only 5–10% of cases, leaving the heritabil-
ity of POAG largely unexplained. Most genetic studies were 
predominantly conducted in European and Asian popula-
tions, leaving African ancestry underrepresented up to now. 
Recent studies in Africans or in cohorts of African descent 
(i.e., Ghana, South Africa and in African Americans) could 
not replicate most of the loci previously identified in GWAS 
of European and Asian populations (Cao et al. 2012; Liu 
et al. 2013; Williams et al. 2015).
Gene finding can be more effective in study popula-
tions where the disease is more common, of earlier onset 
and more severe. Therefore, in this study, we conducted a 
genome-wide meta-analysis using African black and South 
African colored POAG cases and controls, from the Genetics 
In Glaucoma patients from African descent study (GIGA) 
recruited at hospitals from South Africa and Tanzania and 
African Americans enrolled in the BioMe (2018) biobank.
Results
The GIGA dataset consisted of 444 participants from South 
Africa (NPOAG = 297; Ncontrol = 147) and 695 participants 
from Tanzania (NPOAG = 366; Ncontrol = 329). The Tanzanian 
participants were all from the black African origin, 38% of 
South African participants were also from black African 
origin while the remaining 62% were self-reported South 
African Coloured (European, African, Asian admixed). The 
BioMe dataset consisted of POAG cases (N = 450) and con-
trols (N = 1350) and were all African American. The clinical 
and demographic characteristics of the GIGA and BioMe 
participants have been summarized in Table 1.
Association of previously reported POAG loci 
in African populations
First, we tested the association of the 15 previously estab-
lished POAG SNPs identified in GWAS of European and 
Asian populations in the GIGA and BioMe datasets (Bai-
ley et al. 2016; Burdon et al. 2011; Chen et al. 2014; Liu 
et al. 2013; Hysi et al. 2014; Li et al. 2015; Springelkamp 
et al. 2015; Thorleifsson et al. 2010; Wiggs et al. 2012). 
None of these SNPs replicated at a nominal significance 
level (P < 0.05) in any single ethnicity (Supplementary 
Table 1), nor in a combined analysis (Table 2 exact rep-
lication). Because linkage disequilibrium (LD) patterns 
may differ between the study populations of the reported 
GWAS and the current African study participants, we 
also searched for evidence of transferability of the SNPs. 
Locuszoom plots were made using the LD pattern of Euro-
peans and Asians (1000Genomes) to investigate whether 
SNPs in high LD (r2 > 0.8) with the original lead SNP 
showed evidence of association in our study (Supplemen-
tary Fig. 1). This “local” replication strategy queried a 
500 kb window centered on the lead SNP, and yielded a 
total of 246 SNPs in LD (r2 > 0.8) with the 15 lead SNPs. 
Of these 246 SNPs, three SNPs in the TXNRD2, CDKN2B-
AS1, and TMCO1 loci were significantly associated with 
POAG in our study (P < 0.05) (Table 2, local replica-
tion). rs16984299 in TXNRD2 had similar effect size as 
reported by Cook Bailey et al.(Bailey et al. 2016) and 
survived multiple testing  (OR[T] 1.20; 95% CI 1.06–1.35; 
PBonferonni = 0.049) when the association was corrected 
for the effective number of SNPs (N = 16) in the queried 
500 kb window. In addition, we also analyzed three inde-
pendent POAG variants found in African Americans from 
the Women Health Initiative (Hoffmann et al. 2014). We 
found rs192917960 at the RBFOX1 locus associated with 
POAG in BioMe (P = 0.02, Supplementary Table 2), but 
this association did not withstand correction for multiple 
testing.
Next, we compared effect sizes from the combined analy-
sis of GIGA and BioMe with the effect sizes from published 
GWAS reports. In total, 12 out of the 15 known lead SNPs 
had a consistent direction of effect (Supplementary Fig. 2). 
Allele frequencies for most SNPs were very similar in South 
African blacks, Tanzanian, and African American datasets, 
but markedly different compared with the European and 
Asian studies (Supplementary Fig. 3). In eight of the 15 
SNPs, the effect allele had a considerable higher frequency 
Table 1  Demographic and clinical characteristics GIGA study and 
BioMe
GAA genetic African ancestry, IQR interquartile range, POAG pri-
mary open-angle glaucoma, SD standard deviation
Clinical and demographic character-
istics
POAG cases Controls
GIGA 663 476
 Median age, years (IQR) 65.0 (18) 65.0 (12)
 Female, n (%) 281 (42) 266 (56)
 Self-reported ethnicity/race, n (%)
  South African coloured 179 (27) 96 (20)
  African black 484 (73) 380 (80)
 Median proportion GAA, % (IQR)
  South African colored 33.86 (37.26) 33.12 (28.18)
  African black 97.90 (7.80) 97.28 (7.81)
BioMe 450 1350
 Median age, years (IQR) 64.0 (16) 64.0 (16)
 Female, n (%) 290 (64) 870 (64)
 Median proportion GAA, % (IQR) 86.84 (12.84) 86.74 (12.99)
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in Africans while five were clearly less frequent compared 
to Europeans.
To study the contribution of the known SNPs to the risk 
of POAG in GIGA, we calculated a multilocus Genetic Risk 
Score (GRS) based on 15 known SNPs. Three known SNPs 
for TXNRD2, CDKN2B-AS1, and TMCO1 were replaced 
by the proxies that were identified by the local replication 
approach described above. Scores were weighted based 
on the effect sizes found in the GWAS meta-analysis of 
European populations. The GRS, adjusted for age, sex, 
and first five principal components were associated with 
POAG in the GIGA sample (OR 1.56; 95% CI 1.26–1.93; 
P = 4.85 × 10−5). We then stratified the GRS in quintiles, 
and estimated the risk of POAG for each quintile relative 
to the lowest one (Fig. 1). Trend analysis showed a sig-
nificant stepwise increase in the risk of POAG per quintile 
(Ptrend = 2.81 × 10−5), with a twofold increase in POAG risk 
for the highest quintile compared to the lowest. The risk 
attributed to genetics was calculated in reference to the mean 
genetic risk score in the controls. We found that these 15 
known variants taken all together attributed 4% (95% CI 
2–6%) to the overall POAG risk in this study population 
when we adjusted for age, sex and principal components.
Discovery (stage 1)
To identify new loci associated with POAG in African popu-
lations, we performed GWAS using our African ancestry 
datasets. The scheme of the study design is depicted in 
Fig. 2. In the discovery stage, we meta-analyzed GWAS 
results from the GIGA study (South Africa and Tanzania) 
and BioMe (African American) including in total 1113 
POAG cases and 1826 controls. A total of 13.8 million SNPs 
were available after applying our QC and filtering criteria 
(see “Methods” section). The genomic inflation factor was 
0.94 (SE 1.49 × 10−6) and the quantile–quantile plot did not 
show any systemic inflation in the association results, sug-
gesting that confounding by cryptic population stratification 
was unlikely (Supplementary Fig. 4). The discovery associa-
tion results across the whole genome are shown in Fig. 3. 
We identified one novel region reaching genome-wide 
significance (P < 5 × 10−8) in the discovery stage, and two 
suggestive regions (P < 1 × 10−6) (Table 3). The top newly 
associated SNPs were rs141186647[A] an intronic variant 
Fig. 1  Genetic Risk Score. Genetic risk score based on the 15 known 
POAG-loci identified in Europeans and Asians GWAS (rs1192415, 
rs28504591, rs4619890, rs2745572, rs11969985, rs4236601, 
rs284489, rs10712703, rs2472493, rs58073046, rs7137828, 
rs10483727, rs3785176, rs9897123, rs16984299). Participants were 
grouped into quintiles of the genetic risk scores. Green circles repre-
sent the POAG odds ratio (adjusted for age, sex and principal compo-
nents) when comparing each quintile to the lowest quintile (Q1 = ref-
erence line). The green-capped lines represent 95% CI of the POAG 
odds ratios. Bars represent the percentage of POAG cases (dark blue) 
and controls (light blue) per quintile. (Color figure online)
Fig. 2  Study design
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in EXOC4 on chromosome 7 (OR 0.48; P = 3.75 × 10−8), 
rs9475699[A] downstream of DST on chromosome 6 (OR 
1.65; P = 1.25 × 10−7), and rs62023880[A] upstream of 
MNS1 on chromosome 15 (OR 1.39; P = 5.12 × 10−7). The 
regional association plots for these three SNPs are shown in 
Fig. 4. We did not observe any significant heterogeneity for 
these SNPs in the meta-analysis of GIGA and BioMe. The 
association results per ethnic group are provided in Sup-
plementary Table 2, showing similar effects in Tanzanians, 
South Africans, and African Americans. Conditional and 
joint analyses did not identify any additional independent 
signals within the set of SNPs reaching P < 1 × 10−6. Addi-
tionally, we explored if haplotypes encompassing any of 
the three top SNPs were associated with POAG in GIGA 
BioMe, the results for this haplotype association analysis 
are provided in Supplementary Table 3.
Replication of associated variants in African 
populations (stage 2 and stage 3)
All SNPs reaching P < 1 × 10−6 in stage 1 were followed-
up in a replication (stage 2) comprising four independent 
African ancestral studies from South Africa, Ghana, Nigeria 
and African Americans (Eyes of Africa Genetic Consortium; 
Ncases = 2320; Ncontrols = 2121), the South London POAG 
case–control cohort comprising individuals from West 
African origin (Ncases = 378; Ncontrols = 217) and The Afri-
can Descent and Glaucoma Evaluation Study (ADAGES) 
including African Americans (Ncases = 1890; Ncontrols = 2205). 
In total, 22 SNPs at the three independent loci were brought 
forward for replication. Variant rs9475699 (downstream 
of DST) reached a nominal level of statistical significance 
(OR 1.19, P = 0.032) in the Ghanaian study population (Sup-
plementary Table 4). We then performed a meta-analysis 
of all six replication datasets (stage 2), first using a fixed 
effects model, and found no statistical significant replica-
tion (Table 4). Subsequent meta-analysis by means of the 
Han and Eskin random-effects model for SNPs with sig-
nificant (P < 0.05) heterogeneity, also did not identify any 
SNPs with significant association. In stage 3, we performed 
a meta-analysis of all studies (stage 1 + stage 2), totaling 
5701 POAG cases and 6369 controls. Given the high degree 
of heterogeneity observed in the fixed effect meta-analysis 
at this stage, we performed Han and Eskin random-effects 
model. Neither fixed effects nor Han and Eskin random-
effect meta-analysis resulted in genome-wide significant 
signals (Table 4, Supplementary Table 4 and Supplemen-
tary Fig. 5).
Cross‑ethnic validation
We further investigated to what extent loci found in our 
African ancestry GWAS confer a risk of POAG in Euro-
peans. We investigated the top three ranked loci from the 
discovery stage in two independent European ancestry 
studies from the National Eye Institute Glaucoma Human 
Genetics Collaboration (NEIGHBOR) and the Massachu-
setts Eye and Ear Infirmary (MEEI) (totaling 2606 POAG 
cases and 2606 controls) with imputed genotype data 
using the Haplotype Reference Consortium (HRC) (McCa-
rthy et al. 2016). rs141186647 (EXOC4) and rs9475699 
(COL21A1-DST) are rare in the European cohorts but had 
excellent imputation scores (MAF 0.00019, r2 0.987; and 
MAF 0.0023, r2 0.963, respectively). However, neither 
SNP demonstrated significant association in the European 
datasets (rs141186647  OR[A] 5.09; P = 0.39; rs9475699 
 OR[A] 1.27; P = 0.59). SNP rs62023880 (MNS1-ZNF280D) 
on chromosome 15, which was a common variant in the 
Fig. 3  Manhattan plot for the association of genome-wide SNPs 
with primary open-angle glaucoma in GIGA BioMe meta-analysis. 
Manhattan plot of the GWAS meta-analysis of GIGA and BioMe 
(N = 1113cases/N = 1826 controls). The figure shows −log10-trans-
formed P values for all SNPs. The upper dotted horizontal line rep-
resents the genome-wide significance threshold of P < 5.0 × 10−8; the 
lower dotted line indicates a P value of 1 × 10−6. Green dots repre-
sents variants in that are in linkage disequilibrium (r2 > 0.6 1000 
Genomes African ancestry) with the top SNP rs141186647. (Color 
figure online)
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NEIGHBOR/MEEI sample (MAF = 0.15,) also did not 
show statistically significant replication (OR 0.947; 
P = 0.34).
Bioinformatical lookup of functional and regulatory 
effects and expression of POAG‑associated SNPs
We explored the functional and regulatory annotations of 
the three lead SNPs found in the discovery stage, includ-
ing proxy-SNPs within high LD (r2 > 0.8 in 1000G AFR). 
The significant top hit rs141186647 at 7q33 represented 
an intronic variant within the Exocyst Complex Compo-
nent 4 gene (EXOC4). The locus contains a set of SNPs 
in high LD that reside within the introns and within exon 
15 (rs34608222; synonymous) of EXOC4 of which only 
rs79198429 (r2 = 0.92 with rs141186647) is annotated as 
possibly disrupting; transcription factor binding (Regu-
lomeDB score 3a; Supplementary Table 5). This variant is 
located inside a region annotated as an enhancer histone 
mark in multiple tissues by the RoadMap Epigenomics 
Fig. 4  Regional Plots for SNPs P < 1 × 10−6 in the discovery stage (stage 1)
Table 3  Association results for the top SNPs in previously unreported regions with P < 1 × 10−6 in the discovery phase (GIGA + BioMe)
SNP rsID, CHR chromosome, POS base pair; nearest gene (reference NCBI build37) is given as locus label, A1 effect allele, OR odds ratio on 
POAG based on allele A1; Phet P value for heterogeneity
SNP CHR POS Nearest gene A1 Meta-analysis GIGA BioMe
Ncases/Ncontrols Frequency A1 
cases/controls
OR (95% CI) P value I2 Phet
rs9475699 6 56302054 COL21A1-DST A 858/1061 0.22/0.17 1.65 (1.37–1.98) 1.25E−07 41.4 0.1632
rs141186647 7 133634202 EXOC4 A 1113/1826 0.04/0.06 0.48 (0.37–0.62) 3.75E−08 29.2 0.2271
rs62023880 15 56770871 MNS1-ZNF280D A 1113/1826 0.30/0.26 1.39 (1.22–1.58) 5.12E−07 30.4 0.2192
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project, which is predicted to bind the transcriptional coac-
tivator protein P300, and to alter five binding motifs includ-
ing AP-1 transcription factor (Roadmap Epigenomics et al. 
2015). None of the explored SNPs in this region were associ-
ated with eQTL’s.
In silico analyses of SNPs correlated with rs9475699 
located 21 kb downstream the DST gene and rs62023880 
neighboring MNS1 gene did not identify any markers with 
evidence for gene regulatory effects.
To assess the expression of the annotated genes in human 
eye tissues, we examined the online Ocular Tissue Data-
base (https ://genom e.uiowa .edu/otdb/) (Wagner et al. 2013). 
Expression of EXOC4, DST and MNS1 was observed in tis-
sues relevant to POAG, such as the trabecular meshwork, 
optic nerve head and optic nerve. Supplementary Table 6 
depicts the differences in expression levels of these three 
genes across tissue types. In the optic nerve head, the highest 
level of expression was found for DST gene (PLIER 632.5).
Gene‑based tests
We performed gene-based tests using VEGAS2 (2018) on 
the GIGA BioMe meta-analysis results, and first investi-
gated the 15 known POAG genes. None of these were sig-
nificant at a nominal statistical level, the smallest P value 
was found for FOXC1 (P = 0.103, nSNPs = 573) (Supple-
mentary Table 7). We subsequently explored the gene-based 
test results of a total of 25,590 autosomal genes, using a 
Bonferroni corrected gene-based significance threshold of 
Pgene−based < 1.95 × 10−6 (0.05/25590). The EXOC4 gene 
(P = 3.10 × 10−5) did not withstand Bonferroni correction.
Discussion
To date, only European and Asian ancestry GWA studies 
have contributed to the 15 currently known genetic loci for 
POAG. Although the frequency of POAG in persons from 
African descent is high compared to those of European or 
Asian descent, studies of individuals of African descent are 
missing so far. The current study focuses on filling this gap. 
In this case–control study consisting of Africans from the 
African continent as well as of African Americans, we con-
firmed three POAG loci (CDKN2B-AS1, TMCO1, TXNRD2) 
at nominal significance that were previously found in Euro-
peans, and report one novel candidate locus (EXOC4). A 
variant (rs1063192) near CDKNB2-AS1 has previously 
been shown in the Afro-Caribbean population of Barba-
dos, although this study could not replicate other known 
putative loci (Cao et al. 2012). Another insight gained from 
the current study was that the “local approach” rather than 
exact replication yielded these replicable findings in Afri-
cans. Interestingly, these proxy SNPs in Africans have a very Ta
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similar effect size compared to the lead SNP in European 
GWAS.
This study has strengths and limitations. Of particular 
strength was the Pan-African origin of the study participants. 
Previous studies from the African continent were smaller 
and they all focused mainly on West Africans. Our study is 
the first genetic analysis which included East Africans. A 
probable disadvantage of applying a Pan-African approach 
must also be considered. The high genetic diversity present 
across African populations, even when they are geographi-
cally close, may reduce the likelihood of reproducing asso-
ciations in multi-center studies. Other strengths were the 
careful diagnosis of cases, the strict criteria for controls, and 
the application of local replication. Optic discs were graded 
in an objective manner from fundus photographs by glau-
coma experts using internationally accepted standards (Fos-
ter et al. 2002). Controls underwent the same review process 
as cases and had to be over 50 years of age to increase the 
diagnostic certainty of non-disease status. The limitations of 
our study include the relatively low power to detect genome-
wide significance for small effect sizes, as reflected by the 
genomic inflation factor < 1.0, and the lack of a replication 
set from East Africa.
As the genome of African populations is much older, 
genetic diversity is increased, and LD across loci is 
decreased. Rather than focusing only on the lead SNPs 
from European/Asian GWAS, we considered all variants that 
were in strong European/Asian LD with the lead SNPs. We 
analyzed these variants in our African samples, and found 
evidence for nominal replication of three SNPs in TMCO1 
(rs28504591), CDKN2B-AS1 (rs10712703), and TXNRD2 
(rs16984299), of which the latter withstood Bonferroni cor-
rection for the number of effective SNPs. The most signifi-
cant SNP identified in GWAS is often not the causal variant 
(McCarthy and Hirschhorn 2008). We found similar effect 
sizes compared to the European GWAS for the three SNPs 
identified by the local replication approach. The overall 
weaker LD structure in Africans favors proximity of these 
proxy SNPs to the true causal variant. This makes it more 
likely that these proxies are functional. We, therefore, rec-
ommend candidate gene studies in African populations that 
failed to replicate known disease loci found in European or 
Asian populations to use this local approach.
Although this study found evidence that at least one 
known POAG gene plays a role in African glaucoma, we 
could not significantly replicate the remaining 14 associ-
ated SNPs even when we applied the local approach. Yet 
our GRS that was based on known European and Asian 
POAG SNPs showed a significant trend (P = 2.81 × 10−5) 
and a twofold increase in POAG risk comparing extreme 
risk groups. Of note, the allele frequency distributions for 
these SNPs differed markedly between our African study 
and the original European/Asian studies. This points towards 
differences in genetic architecture, and makes it difficult to 
estimate statistical power.
This study identified a novel candidate variant within 
the EXOC4 gene in the meta-analysis of GIGA and BioMe. 
Recent reports provide evidence that this gene is implicated 
in cognitive traits as intelligence and educational attainment, 
and is also associated with the neurodegenerative Alzhei-
mer’s disease (Okbay et al. 2016; Sherva et al. 2014; Sniek-
ers et al. 2017). The EXOC4 gene is ubiquitously expressed, 
and is particularly abundant in the brain. EXOC4 encodes the 
SEC-8 protein, a component of a complex which is essential 
for exocytosis; it directs Golgi-derived secretory vesicles 
to specific docking sites on the plasma membrane. Exocyst 
proteins are needed for rapid membrane expansion, which 
happens during outgrowth of neurons and synaptogenesis. 
So far, the exocyst complex has not been studied in con-
nection with glaucomatous optic neuropathy, however, it is 
expressed in the trabecular meshwork. In this tissue, it plays 
a role in the formation of invadopodia, protrusions that are 
important for releasing matrix metalloproteinase into the 
extracellular matrix to decrease trabecular outflow resist-
ance (Han et al. 2013). Strikingly, our African POAG cases 
had high IOP, and it is intriguing to speculate that EXOC4 
contributes to POAG by interfering with matrix metallopro-
teinase release and trabecular outflow.
Replication of our genome-wide significant finding from 
the discovery set in our other African studies was challeng-
ing for this relatively rare variant. Meta-analysis of the dis-
covery and replication stage showed considerable variation 
in effect size and direction of effect between the discovery 
and the replication set, indicating substantial heterogeneity. 
This heterogeneity is likely to be caused by differences in 
genetic ancestry as most of the replication studies were from 
the West-African origin, while the population GIGA BioMe 
included a substantial proportion of persons from East 
Africa. Differences in LD pattern between causal variants 
and identified markers as shown in Supplementary Fig. 7 
can cause this directionally inconsistent association across 
studies more commonly known as the flip-flop phenomenon 
(Lin et al. 2007).
In conclusion, we conducted the first GWAS of POAG 
comprising continental Africans. We verified the European 
glaucoma gene TXNRD2 and identified a novel candidate 
locus encompassing EXOC4 that requires further follow 
up in large African studies. A GRS combining the effects 
of the known POAG SNPs indicated that these SNPs are 
implicated to play a role in African POAG. Future studies 
on POAG in Africa should take the substantial genetic het-
erogeneity into account by ascertaining large discovery and 
replication sets from the same geographic area.
855Human Genetics (2018) 137:847–862 
1 3
Methods
Study population
The Genetics In Glaucoma patients from African descent 
study (GIGA) is a multicenter case–control study compris-
ing POAG patients and controls from South Africa and Tan-
zania. Participants from Black African and South African 
Coloured ancestry were ascertained from the ophthalmology 
outpatient department of the Groote Schuur Hospital in Cape 
Town, South Africa (Ncases = 327; Ncontrols = 194), and from 
hospitals in Tanzania: Muhimbili National Hospital and 
CCBRT Disability Hospital in Dar es Salaam (Ncases = 395; 
Ncontrols = 382). The study was conducted according to the 
guidelines for human research by the National Institute 
for Medical Research in Tanzania. Ethical approval was 
obtained from the institutional review boards at each study 
site, and written informed consent was provided by each 
participant.
The Charles Bronfman Institute for Personalized Medi-
cine BioMe BioBank is an electronic medical record 
(EMR)-linked clinical care biobank that integrates research 
data and clinical care information of patients at The Mount 
Sinai Medical Center New York. This center serves diverse 
local communities of upper Manhattan with broad health 
disparities including POAG. The current analysis includes 
participants who self-reported to be of African ancestry 
(Ncases = 450; Ncontrols = 1350) who were enrolled between 
September 2007 and October 2014. Ethical approval was 
obtained from the institutional review boards at Mount 
Sinai, and written informed consent was obtained from all 
participants.
Phenotype definition
In GIGA, POAG cases met category 1 or 2 of the ISGEO 
classification for open-angle glaucoma (Foster et al. 2002). 
In brief, cases had either a definite visual field defect and 
Vertical Cup Disc Ratio (VCDR) ≥ 0.7, or VCDR > 0.8 in 
the absence of a visual field test. Other inclusion criteria 
were an open angle on gonioscopy and age of onset older 
than 35 years. Glaucoma patients diagnosed with second-
ary causes were excluded from this study. Controls were 
recruited at the same ophthalmology clinics and underwent 
identical examinations as the POAG cases. Inclusion criteria 
were: no signs of glaucoma, IOP ≤ 21 mmHg; VCDR < 0.5, 
and a VCDR inter-eye asymmetry < 0.2, no family history 
of glaucoma, and age > 55 years. Case and control status 
was adjudicated by two experienced ophthalmologists (AT 
and HL).
In BioMe information on POAG status, sex, age 
was derived from patients’ EMR. POAG patients were 
considered cases if they had ≥ 1 diagnoses for POAG (ICD-9 
codes 365.01, 365.05, 365.11, 365.12 or ICD-10 code 
H40.11). Participants with pre-glaucoma (ICD-9 code 365), 
ocular hypertension only (ICD-9 code 365.04), unspecified 
glaucoma (ICD-9 code 365.10) or with secondary glaucoma 
(Supplementary Table 8) were excluded from the analyses. 
Details of the ICD-9 or ICD-10 codes used can be found 
in Supplementary Table 9. Controls were those of African 
ancestry over 40 years of age not being diagnosed with any 
type of glaucoma.
Genotyping
In GIGA, 1162 participants were genotyped using either the 
Illumina HumanOmniExpressExome Beadchip (964,193 
variants; Illumina, Inc., San Diego, CA, USA; n = 999) or the 
Illumina HumanOmni2.5Exome Beadchip (2,406,945 vari-
ants; Illumina, Inc., San Diego, CA, USA; n = 163). Exten-
sive quality control (QC) was performed on the genotyped 
data in PLINK v1.07 (Purcell et al. 2007). Variants with 
a call rate < 95%, as well as variants showing an extreme 
deviation from Hardy–Weinberg equilibrium (P < 1 × 10−6), 
or MAF < 0.01 were excluded. All SNPs were mapped to 
genome build hg19/GRCh37. Individual level QC was per-
formed by exclusion of individuals with a call rate < 95%, 
discordant sex in self-report versus genetically determined 
sex, excess or reduced heterozygosity, relatedness (PI-
HAT > 0.25) or duplicative samples based on identity by 
descent (IBD) sharing calculations. The final dataset con-
sisted of 663 and 476 successfully genotyped POAG cases 
and controls, respectively.
Participants from BioMe were genotyped on either Illu-
mina HumanOmniExpressExome-8 v1.0 beadchip array 
or the illumina Multi-Ethnic Genotyping Array (MEGA). 
As in GIGA, QC was performed following a similar proto-
col. Exclusion of variants was based on a call rate < 95%, 
extreme deviation from Hardy–Weinberg equilibrium 
(P < 1 × 10−5), or MAF < 0.01. Individual level QC excluded 
samples with a call rate < 95%, gender mismatches, ethnic 
outliers, excess or reduced heterozygosity and first degree 
relatives or duplicates.
Imputation
Imputation of unknown genetic variation was performed by 
means of the “cosmopolitan” approach of using all available 
populations in a reference panel. The 1000 Genomes Pro-
ject phase III version 5 was used as an imputation reference 
panel for GIGA (Genomes Project et al. 2015). The pipe-
line implemented at the Michigan Imputation Server (https 
://imput ation serve r.sph.umich .edu) was used for prephasing 
and imputation (Minimac) of GIGA genotypes (Das et al. 
2016). Imputations of BioMe genotypes were carried out 
856 Human Genetics (2018) 137:847–862
1 3
with the program IMPUTE using the 1000 Genomes pro-
ject phase I version 3 as a reference (Genomes Project et al. 
2012; Howie et al. 2009).
Population structure
In GIGA, the population structure was examined by prin-
cipal-components analysis (PCA) in PLINK v1.9 (Chang 
et al. 2015); PCA plots for each array and population are 
displayed in Supplementary Fig. 8. Scree plots were exam-
ined to determine the number of principal-components (PC) 
for adjustment of potential population stratification (shown 
in Supplementary Fig. 9). The first five PCs were used as 
covariates for South African samples, the first four for Tan-
zanian samples.
In BioMe, population structure (Supplementary Fig. 8) 
was controlled for by means of genetic matching using the 
first two PCs. Additional matching was performed based on 
age and sex.
Replication
The Eyes of Africa Genetic Consortium, the South Lon-
don POAG case–control cohort and The African Descent 
and Glaucoma Evaluation Study (ADAGES III) served as 
replication panels. The Eyes of Africa Genetic consortium 
is a Pan-African study of genetic determinants of POAG, 
and comprises studies recruited from Ghana, Nigeria, South 
Africa and the USA, totaling a sample size of 2320 POAG 
cases and 2121 controls. The methods of ascertaining POAG 
cases has been described in detail elsewhere (Liu et al. 
2013). In brief, POAG cases met the following inclusion cri-
teria: glaucomatous optic neuropathy (VCDR > 0.7 or notch 
in the neuroretinal rim), and visual field loss (examined 
by frequency doubling technology or standard automated 
perimetry) consistent with optic nerve damage in at least one 
eye. Controls were participants with no known first-degree 
relative with glaucoma, IOP less than 21 mmHg in both eyes 
without treatment, and no evidence of glaucomatous optic 
neuropathy in either eye. Genotyping of cases and controls 
was performed on the Illumina OmniExpressExome array. 
Genotype QC is described in Supplementary Appendix 2.
The South London POAG case–control cohort consists of 
378 POAG patients and 217 controls of West African ances-
try residing in the United Kingdom. Patients were recruited 
from glaucoma clinics in South London and included if 
they had visual field loss in at least one eye attributed to 
glaucoma by a glaucoma specialist, had a VCDR of more 
than 0.6, were receiving intraocular-lowering medication 
(or had previous surgery), and had open drainage angles on 
gonioscopy. Controls were recruited from other eye clin-
ics and were included if the examining ophthalmologist 
deemed there was no sign of POAG, had healthy optic discs 
(VCDR < 0.6), and normal intraocular pressure without any 
IOP-lowering therapy (< 20 mmHg). The majority of con-
trols did not have formal visual field testing. Genotyping was 
performed in a single batch using Illumina’s OmniExpress 
array. Genotype QC has been described in the Supplemen-
tary Appendix 2.
The African Descent and Glaucoma Evaluation Study 
(ADAGESIII) is a large collection of African American 
POAG patients and healthy controls recruited at five eye 
centers in the US (La Jolla, California; New York, New 
York; Birmingham, Alabama; Houston, Texas; Atlanta, 
Georgia). The methods of recruitment and selection of 
POAG cases have been described previously (Zangwill 
et al. 2018). In brief, eligibility for inclusion as a POAG 
case required glaucomatous visual field damage defined as a 
pattern standard deviation or glaucoma hemifield test results 
outside normal limits. If good-quality visual fields were not 
available glaucomatous optic disc damage defined as evi-
dence of excavation, neuroretinal rim thinning or notching, 
localized or diffuse retinal nerve fiber layer defect, or an 
inter-eye asymmetry of the vertical cup-to-disc ratio of more 
than 0.2 was required. Controls were ascertained at Wake 
Forest School of Medicine. Details on genotyping and QC 
are summarized in the Supplementary Appendix 2.
Statistical analysis
We conducted a three-stage GWAS. Stage 1 was aimed at 
the discovery and consisted of a meta-analysis on summary 
data from GIGA and BioMe. Stage 2 included replication of 
independent and lead SNPs identified at stage 1 reaching a 
significance level P < 1 × 10−6. Stage 3 combined all results 
in an overall meta-analysis.
Genome-wide association testing in the GIGA study 
assumed an additive genetic model adjusting for sex and age 
and included the aforementioned PCs of the principal-com-
ponents analysis. Association analyses were carried out in 
EPACTS (http://www.sph.umich .edu/csg/kang/epact s/index 
.html) by means of the Firth bias-corrected likelihood-ratio 
test (Firth 1993). In BioMe SNPTEST was applied (https 
://mathg en.stats .ox.ac.uk/genet ics_softw are/snpte st/snpte 
st.html) using the frequentist association tests implemented 
in the program, based on an additive model (Marchini et al. 
2007). Cases and controls were matched by age, sex and the 
first two principal components in a 1:2 case/control ratio. To 
control for genotype uncertainty, we used the missing data 
likelihood score test (the score method).
Stage 1
A centralized filtering was performed on GIGA and BioMe 
GWAS results prior to the meta-analysis. Summary result 
files were assessed and filtered for monomorphic SNPs 
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and SNPs with a minor allele frequency < 0.01. SNP’s 
that failed or had low-quality imputation, i.e. Minimac r2/
SNPTEST INFO < 0.5, were also excluded. The cleaned 
summary statistics of both studies were then meta-ana-
lyzed by means of an inverse variance fixed effects meta-
analysis implemented in METAL (Willer et  al. 2010). 
Summary statistics were corrected using the ‘genomic-
control’ option in METAL to eliminate any residual bias. 
Only variants present in GIGA South Africa, GIGA Tan-
zania, as well as BioMe were taken for further analysis.
We searched for evidence of replication of the 15 
known POAG variants found in European and Asian GWA 
studies by employing two replication strategies. First, we 
used the “exact” approach that involves only the lead sig-
nificant markers. P values at each known POAG SNP in 
our study were examined and a P < 0.05 was considered 
as evidence for statistically significant replication. Next, 
we analyzed the transferability of SNPs by applying the 
“local” approach. All SNPs in strong LD (r2 > 0.8) with 
the known POAG SNP in the1000 Genomes European 
population were analyzed. For evidence of local transfer-
ability, P values were adjusted for the number of effective 
SNPs within a locus as determined by the Genetic Type I 
Error Calculator (2018) (Li et al. 2012).
To identify potential additional independent signals 
nearby the lead SNP in the meta-analysis of GIGA and 
BioMe, we conducted a conditional analysis implemented 
in Genome-wide complex trait analysis (GCTA 2018) soft-
ware, using the cojo method, which performs conditional 
and joint analyses with model selection (Yang et al. 2011). 
The genome-wide meta-analysis summary statistics from 
the discovery stage were used as the input data. Within 
the GCTA analysis, MAF was restricted to ≥ 1% and 
P < 1 × 10−6. For this analysis, we used the GIGA Tanza-
nia 1000 Genome phase 3 imputed data to calculate LD 
between pairwise SNPs. SNPs further than 10 Mb apart 
were assumed to be in LD.
We next applied haplotype association analysis to iden-
tify POAG associated haplotypes that harbor the variants 
identified in the discovery stage with P < 1 × 10−6. The 
haplotype association analysis comprised two steps. First, 
pairwise measures of LD were calculated in Haploview 
to identify LD blocks (LD) (Gabriel et al. 2002). Second, 
significant haplotypes were identified using a Chi-squared 
test implemented in Haploview (Barrett et al. 2005).
Stage 2
SNPs put forward for replication were first assessed in each 
replication sample. P value thresholds for significance were 
adjusted for the number of SNPs tested by the Bonferroni 
method. Results of all five replication studies were subse-
quently combined in an inverse variance meta-analysis.
Stage 3
Finally, results from stage 1 and 2 were combined in a tran-
sethnic meta-analysis. SNPs showing evidence of effect 
heterogeneity between studies (Phet < 0.05) were ana-
lyzed using the Han Eskin random-effects model (Han and 
Eskin 2011). This analysis implemented in METASOFT 
software increases the power to detect associations under 
heterogeneity.
Power analysis
Power analysis was performed using the Power for Genetic 
Association analyses (PGA) package (Menashe et al. 2008). 
For replication of known POAG SNPs power analysis 
showed that for α = 0.05/15 tests, (Supplementary Fig. 6 
red line) and minor allele frequencies of 0.05, 0.10, 0.25; 
minimal OR’s of 1.5, 1.35 and 1.25, respectively, could be 
detected at statistical significance assuming 80% power. For 
genome-wide analysis in the discovery stage, we had > 80% 
power given an alpha of 5 × 10−8 to detect variants with odds 
ratios of 1.89 and 3.25 for effect allele frequencies of 0.05 
and 0.01, respectively (Supplementary Fig. 6 green line). 
For validation of SNPs in stage 2, we had > 80% power at 
an alpha of 0.05/3 independent SNPs = 0.017 to detect loci 
with odds ratios of 1.29 and 1.7 for effect allele frequencies 
of 0.05 and 0.01, respectively (Supplementary Fig. 6 line 
blue line).
Bioinformatics analysis
Several bioinformatics tools to assess whether SNPs or their 
linked genetic variants were associated with a putative func-
tion that might affect patient outcomes were consulted. Hap-
loReg v4.1 and the RegulomDB v1.1 that include Genotype-
Tissue Expression (GTEx) database from the Encyclopedia 
of DNA Elements (ENCODE) project were used to identify 
the regulatory potential on candidate functional variants to 
examine the particular tracks of interest, such as TF-ChIP 
signals, DNase peaks, DNase footprints and predicted DNA 
sequence motifs for transcription factors (Boyle et al. 2012; 
Ward and Kellis 2012). The GTEx data were used to iden-
tify the correlations between SNPs and whole-blood-specific 
gene expression levels. The Ocular Tissue Database (2018) 
(IOWA) was checked for expression of associated genes in 
relevant ocular tissue, in which levels of gene expression are 
indicated as Affymetrix Probe Logarithmic Intensity Error 
(PLIER) normalized value [with normalization in PLIER as 
described in Wagner et al. 2013].
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Gene‑based tests
We performed a gene-based test in VEGAS2 (Mishra and 
Macgregor 2015) to confirm known POAG genes and to 
identify additional loci not reaching genome-wide signifi-
cance in a single marker-based analysis. VEGAS2 examines 
the association from all SNPs across a gene and corrects for 
gene size and LD between SNPs. The 1000 Genomes phase 
3 African populations were downloaded from the VEGAS 
website and used as the reference panel for pairwise LD 
correlations. SNPs were allocated to one or more autosomal 
genes using customized gene boundaries of ± 10 kb.
Genetic risk score
To further evaluate to which extent known POAG SNPs con-
fer risk in our study, a genetic risk score (GRS) was calcu-
lated in the GIGA dataset. Fifteen well imputed/genotyped 
(Minimac r2 > 0.5) SNPs that were previously reported in 
large GWAS were used for constructing the GRS. For each 
individual, a weighted GRS was computed by multiplying 
the number of effect alleles with the log (OR) reported in 
the literature. We assessed the association of the GRS with 
POAG in a logistic regression model adjusting for sex, age 
and PCs. An estimation of the attributable genetic risk was 
calculated using the R package “attribrisk”.
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